-
AACR 2022: Sotorasib shows stunning 2-year survival in KRAS G12C+ NSCLC
Time of Update: 2022-05-18
Table efficacy analysisMain results: The 2-year overall survival (OS) rate of sotorasib (Lumakras) in patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC) was 32.
-
AACR 2022: Phase II trial of perioperative pembrolizumab in combination with capecitabine and oxaliplatin and adjuvant pembrolizumab in resectable gastric and gastroesophageal junction (GC/GEJ) adenocarcinoma
Time of Update: 2022-05-18
At the 2019 ASCO meeting, the latest results of the KEYNOTE-062 study were announced, including 763 patients with locally advanced, HER2-negative, unresectable or metastatic GC/GEJC with PD-L1 CPS ≥ 1
-
2022 AACR: ORR exceeds 60%, local innovative drug Gumetinib is expected to bring a new treatment option for METex14 skip mutation NSCLC patients!
Time of Update: 2022-05-18
2022(2022 AACR)48—13, 。、MET(SCC244)IIGLORYAACR,—— 。2022(2022 AACR)48—13, 。、MET(SCC244)IIGLORYAACR,—— 。The study showed that in the treatment of non-small cell lung cancer ( NSCLC ) patients with MET exon 14 (MET ex14) skipping mutations, the overall population objective response rate ( ORR ) was 60.
-
Nat Commun: HMMR overexpression increases the risk of BRCA1-related breast cancer
Time of Update: 2022-05-18
HMMR (hyaluronan-mediated motor receptor) interacts with BRCA1 and further regulates cell division and apical-basolateral polarization in mammary epithelial cellsIn this study, by analyzing human germline cell and tumor-related data, and at the molecular and cellular levels in mouse models, we describe the relationship between molecular, cellular, and tissue microenvironmental changes in BRCA1-related breast cancer risk.
-
The AACR blockbuster RATIONALE-304: Clinical study of tumor mutational burden (TMB) versus tislelizumab (TIS) + chemotherapy (chemo) versus chemotherapy alone in the first-line treatment of advanced non-squamous non-small cell lung cancer (nsq-NSCLC) outcome study
Time of Update: 2022-05-18
NSCLCRecently, the RATIONALE-304 study, led by Shanghai Chest Hospital, reported at AACR biomarker analysis of baseline tissue and blood TMB (tTMB and bTMB, respectively) .
Recently, the RATIONALE-304 study, led by Shanghai Chest Hospital, reported at AACR biomarker analysis of baseline tissue and blood TMB (tTMB and bTMB, respectively) .
-
Radiology: MRI radiomics pathological prediction after chemoradiotherapy for rectal cancer
Time of Update: 2022-05-18
ADC = apparent diffusion coefficient, T2WI = T2-weighted imagingThe present study demonstrates that in patients with locally advanced rectal cancer following neoadjuvant chemotherapy (nCRT), an MRI-based radiomics model demonstrated better classification performance than radiologist qualitative assessment in diagnosing pathological complete response (pCR) .
-
NICE recommends Koselugo for neurofibromatosis type 1
Time of Update: 2022-05-18
This therapy is indicated for the treatment of symptomatic and inoperable plexiform neurofibromatosis (PN) associated with neurofibromatosis type 1 (NF1) in children three years of age and older .
Therefore, this Phase II trial concluded that most children with neurofibromatosis type 1 and inoperable plexiform neurofibromas experienced significant clinical benefit with Koselugo .
-
Br J Cancer: 5-aminolevulinic acid increases mitochondrial reactive oxygen species production and reduces radioresistance in prostate cancer
Time of Update: 2022-05-18
5-Aminolevulinic acid overcomes hypoxia-induced radiation resistance by enhancing mitochondrial reactive oxygen species production in prostate cancer cells.
5-Aminolevulinic acid overcomes hypoxia-induced radiation resistance by enhancing mitochondrial reactive oxygen species production in prostate cancer cells.
-
European Radiology: Application of multimodal MRI-based radiomics approach in predicting response to gamma knife radiotherapy after brain metastases from lung cancer
Time of Update: 2022-05-18
c, d ROC curves of radiomics nomograms in the primary and validation cohorts In conclusion, this study developed a radiomics approach integrating multimodal MRI-based radiomics features and clinical factors to predict post-treatment response of LCBM to GKRS .
-
Science: Genome-wide analysis of somatic noncoding mutational patterns in cancer
Time of Update: 2022-05-18
Related research results were published in the April 8, 2022 issue of the journal Science, with the title "Genome-wide analysis of somatic noncoding mutation patterns in cancer" .
-
AACR 2022: NK Cells and Bispecific Antibody AFM13 Complexes Consistently Induce Lymphoma Remission
Time of Update: 2022-05-18
The complex of the bispecific antibody AFM13 with NK cells continued to induce remission in patients with relapsed CD30 + lymphoma , results from a phase I/II study presented Sunday at the American Association for Cancer Research (AACR) annual meeting .
-
European Radiology: The value of MRI in predicting pathological complete response to neoadjuvant chemotherapy in breast cancer patients
Time of Update: 2022-05-18
Final pathology report after surgery showed no pCR (ypT1)In conclusion, MRI images of HR-/HER2+ subtype breast cancer after NAC tend to have similar imaging findings to residual malignancy, even when pCR is achieved .
-
J Clin Oncol: Efficacy of EGFR inhibitors in the treatment of EGFR-amplified gastroesophageal junction cancer
Time of Update: 2022-05-18
A sub-analysis of a phase 3 trial of an epidermal growth factor receptor inhibitor (EGFRi) shows that EGFRi improves outcomes in patients with EGFR-amplified gastroesophageal junction cancer (GEA), but data from a larger analysis are lacking .
-
Blood: Scientists identify novel genetic target to treat adult blood cancer
Time of Update: 2022-05-18
org/blood/article-abstract/139/10/1541/482776/Genome-wide-CRISPR-screen-identifies-CDK6-as-a?redirectedFrom=fulltext"Our findings suggest that CDK6 may be a very attractive target for the treatment of ATLL, and that in some ATLL cell lines, loss of TP53 function may render cells resistant to the CDK6 inhibitor Palbociclib," said researcher Nakagawa.
-
AACR's blockbuster SPOTLIGHT203 trial: efficacy of intratumoral injection of BO-112 combined with pembrolizumab in patients with advanced melanoma resistant to PD-1 immunotherapy
Time of Update: 2022-05-18
This is a single-arm study (NCT04570332) of intratumoral BO-112 and intravenous pembrolizumab in patients with melanoma (skin, condyloma, or mucosa) receiving anti-PD1 therapy and confirmed progressive disease (PD) .
-
Sub-Journal of Science: Using hydrogels to deliver CAR-T cells could improve the treatment of solid tumors
Time of Update: 2022-05-18
Related research results were published in the journal Science Advances on April 8, 2022, with the title "Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors" .
-
STTT: Sun Yat-Sen Medical College identified a specific receptor for the M1 virus!
Time of Update: 2022-05-18
After the team of Professor Yan Guangmei of our hospital originally identified M1 virus as a new type of oncolytic virus in 2014 (PNAS, 2014), four intracellular biomarkers for predicting the efficacy of M1 virus were successively discovered, namely zinc Refers to antiviral protein ZAP (Oncogene, 2020), cholesterol pathway-related protein RHOQ (Nature Communications, 2018), endoplasmic reticulum stress pathway protein IRE1α (Journal of Virology, 2018) and KRAS mutation (Molecular Oncology, 2020) .
-
AACR Blockbuster: Combination of high gene amplification and tumor mutational burden as a pan-cancer biomarker in patients receiving tislelizumab
Time of Update: 2022-05-18
A high tumor mutational burden (TMB-H) was associated with elevated neoantigen expression in tumors and increased response to PD-(L)1 inhibitors .
A high tumor mutational burden (TMB-H) was associated with elevated neoantigen expression in tumors and increased response to PD-(L)1 inhibitors .
-
AACR 2022: Olaparib in combination with cyclophosphamide and metformin performs well in endometrial cancer (ENDOLA trial)
Time of Update: 2022-05-18
metforminENDOLA is a phase 1/2 open-label, dose-escalation trial evaluating olaparib in combination with cyclophosphamide and metformin metronomic therapy in elderly patients with multiple prior therapy for recurrent advanced endometrial cancer .
-
Nature Genetics: Why don't most smokers get lung cancer?
Time of Update: 2022-05-18
Nature Genetics Single-cell analysis of somatic mutations in human bronchial epithelial cells in relation to aging and smokingUsing single-cell sequencing technology, the study found that some of the most smokers may have powerful "self-protection mechanisms" that limit the DNA mutations caused by smoking to protect themselves from lung cancer .